Bioventus11.10.20
Beginning Jan. 1, Bioventus, a global leader in Innovations For Active Healing, will gain preferred access through the CVS Caremark Formulary, to DUROLANE, GELSYN-3, and SUPARTZ FX, for the treatment of knee osteoarthritis (OA) pain. CVS Caremark manages the drug benefits for more than 40 million lives, which includes the prescription drug benefits of 6 million Aetna members.
DUROLANE, is a single-injection, GELSYN-3, a three-injection, and SUPARTZ FX, a five-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. All three products will be among the four preferred standard formulary options of knee OA treatments for CVS Caremark members.
“CVS Caremark members now have access to the broadest HA portfolio available to patients and physicians in the US,” said John Nosenzo, chief commercial officer, Bioventus. “DUROLANE, GELSYN-3 and SUPARTZ FX, all from Bioventus, provide long lasting OA knee pain relief allowing patients to resume more active lives.”
DUROLANE, is a single-injection, GELSYN-3, a three-injection, and SUPARTZ FX, a five-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. All three products will be among the four preferred standard formulary options of knee OA treatments for CVS Caremark members.
“CVS Caremark members now have access to the broadest HA portfolio available to patients and physicians in the US,” said John Nosenzo, chief commercial officer, Bioventus. “DUROLANE, GELSYN-3 and SUPARTZ FX, all from Bioventus, provide long lasting OA knee pain relief allowing patients to resume more active lives.”